Before testing the impact of CPI-613 on a subpopulation of ovarian CSCs, the baseline CD133 and CD117 levels were determined in the five ovarian serous cancer cell lines used in our study. This evidence concerns the gene KIT and ovarian serous adenocarcinoma.